Cantor Fitzgerald set a $16.00 price target on Nabriva Therapeutics AG (NASDAQ:NBRV) in a report issued on Tuesday, July 11th. The firm currently has a buy rating on the biotechnology company’s stock.

NBRV has been the subject of a number of other research reports. Needham & Company LLC restated a buy rating and set a $15.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, March 27th. HC Wainwright restated a buy rating on shares of Nabriva Therapeutics AG in a research report on Friday, May 12th. ValuEngine upgraded shares of Nabriva Therapeutics AG from a sell rating to a hold rating in a research report on Saturday, June 24th. Wedbush restated an outperform rating and set a $13.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, May 15th. Finally, Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a hold rating to a buy rating and set a $11.00 target price for the company in a research report on Saturday, May 27th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and six have issued a buy rating to the stock. The stock currently has an average rating of Buy and a consensus price target of $15.43.

Shares of Nabriva Therapeutics AG (NASDAQ:NBRV) traded up 6.06% on Tuesday, hitting $10.50. 53,244 shares of the stock traded hands. The firm’s market cap is $28.57 million. Nabriva Therapeutics AG has a 52 week low of $3.52 and a 52 week high of $12.75. The stock has a 50-day moving average price of $10.26 and a 200 day moving average price of $10.28.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.thecerbatgem.com/2017/08/07/nabriva-therapeutics-ag-nasdaqnbrv-pt-set-at-16-00-by-cantor-fitzgerald-updated-updated-updated.html.

In other Nabriva Therapeutics AG news, Director George Harrison Talbot sold 325 shares of the firm’s stock in a transaction dated Thursday, May 25th. The shares were sold at an average price of $100.56, for a total transaction of $32,682.00. Following the transaction, the director now owns 3,854 shares of the company’s stock, valued at approximately $387,558.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, major shareholder Hbm Healthcare Investments (Ca sold 2,695 shares of the firm’s stock in a transaction dated Friday, July 7th. The shares were sold at an average price of $10.52, for a total transaction of $28,351.40. Following the transaction, the insider now directly owns 2,569,315 shares in the company, valued at approximately $27,029,193.80. The disclosure for this sale can be found here. In the last three months, insiders sold 205,115 shares of company stock worth $2,252,057.

Several hedge funds have recently added to or reduced their stakes in the stock. Renaissance Technologies LLC purchased a new stake in Nabriva Therapeutics AG during the fourth quarter worth $103,000. Almanack Investment Partners LLC. purchased a new stake in Nabriva Therapeutics AG during the first quarter worth $1,870,000. Nationwide Fund Advisors purchased a new stake in Nabriva Therapeutics AG during the first quarter worth $2,074,000. Finally, Wellington Management Group LLP boosted its stake in Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares in the last quarter. Institutional investors and hedge funds own 56.65% of the company’s stock.

Nabriva Therapeutics AG Company Profile

Nabriva Therapeutics plc is a clinical stage biopharmaceutical company. The Company is engaged in engaged in the research and development of novel anti-infectives to treat serious infections, with a focus on the pleuromutilin class of antibiotics. The Company’s medicinal chemistry has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations of its lead product candidate, lefamulin.

Analyst Recommendations for Nabriva Therapeutics AG (NASDAQ:NBRV)

Receive News & Stock Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related stocks with our FREE daily email newsletter.